Unique ID issued by UMIN | UMIN000020632 |
---|---|
Receipt number | R000023801 |
Scientific Title | Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes (randomized controlled clinical trial) |
Date of disclosure of the study information | 2016/01/20 |
Last modified on | 2016/01/19 14:15:12 |
Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes (randomized controlled clinical trial)
Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes
Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes (randomized controlled clinical trial)
Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes
Japan |
Hypertension with type 2 diabetes mellitus
Cardiology |
Others
NO
To compare the effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker in patients with hypertension and type 2 diabetes
Efficacy
The change in ambulatory blood pressure (nighttime SBP) between baseline and after 12 weeks of treatment
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Olmesartan medoxomil 40 mg daily
Olmesartan medoxomil 20 mg plus azelnidipine 16 mg daily
20 | years-old | <= |
Not applicable |
Male and Female
(1) hypertension
(2) age >= 20
(3) type 2 diabetes
(1) secondary hypertension
(2) past histody of cardiovascular disease
(3) resistant hypertension
(4) inadequacy for this therapy
(5) severe renal dysfunction (eGFR < 45 mL/min/1.73m2)
(6) severe liver dysfunction (Child-Pugh: class B or C)
(7) having malignancy or collagen disease
(8) chronic Af
(9) pregnancy or lactation in women
(10) history of allergy for olmesartan medoxomil or azelnidipine
110
1st name | |
Middle name | |
Last name | Norihiro Furusyo |
Kyushu University Hospital
Department of General Internal Medicine
3-1-1, Maidashi, Higashi-ku, Fukuoka
092-642-5909
furusyo@gim.med.kyushu-u.ac.jp
1st name | |
Middle name | |
Last name | Motohiro Shimizu |
Kyushu University Hospital
Department of General Internal Medicine
3-1-1, Maidashi, Higashi-ku, Fukuoka
092-642-5909
smotohir@gim.med.kyushu-u.ac.jp
Department of General Internal Medicine, Kyushu University Hospital
None
Self funding
NO
2016 | Year | 01 | Month | 20 | Day |
Unpublished
Open public recruiting
2013 | Year | 12 | Month | 26 | Day |
2014 | Year | 01 | Month | 01 | Day |
2016 | Year | 01 | Month | 19 | Day |
2016 | Year | 01 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023801
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |